Apreo Health, Inc.

Apreo Health, Inc. , based in the US, develops advanced investigational devices focused on improving lung disease management through innovative healthcare technologies that enhance patient outcomes. Apreo Health, Inc. specializes in developing solutions for lung diseases.

Founded in 2018 and headquartered in Menlo Park, US. In August 2025, Apreo Health, Inc. raised USD 81. 84 million in Series B funding co-led by investors Bain Capital Life Sciences and Norwest Venture Partners, with participation from investors F-Prime Capital and Intuitive Ventures, Lightstone Ventures and Sante Ventures.

Apreo Health specializes in developing innovative solutions aimed at addressing lung diseases through its investigational devices. The company focuses on transformative healthcare technologies designed to enhance patient outcomes, specifically addressing conditions that impair lung function. Apreo Health’s products are tailored for clinical investigations and are utilized primarily in medical settings where lung disease management is critical. The company serves a diverse client base that includes healthcare providers, hospitals, and research institutions, ensuring that their solutions are accessible to patients in need of lung disease treatment.

Apreo Health's offerings are positioned in various geographical markets, catering to both domestic and international healthcare sectors. Apreo Health's revenue model is primarily structured around direct partnerships with healthcare institutions and clinical research organizations, facilitating the distribution of their investigational devices. Transactions typically occur through direct sales to hospitals and healthcare facilities engaged in clinical investigations, where the focus is on improving patient care for lung diseases. The company’s flagship products, which are protected under trademarks like 'Making Every Breath Count,' are integral to its offerings, supporting a revenue framework that aligns with clinical needs.

While specific pricing plans for individual products or services are not disclosed, the sales strategy emphasizes long-term relationships with healthcare providers to foster continued engagement and usage of Apreo Health’s innovative solutions. Apreo Health, Inc. plans to utilize the USD 130. 00 mn raised in the Series B funding to support a pivotal clinical trial, regulatory activities, and early commercialization of its airway scaffold implant for severe emphysema.

The company aims to expand its reach into new markets and geographic regions, although specific targets and timelines have not been disclosed. The recent funding will play a crucial role in advancing these strategic initiatives.